Evidence map›Paper›PMID 40657808›Full record

ArticleSleep2025

Narcolepsy and risk of cardiovascular outcomes beyond stimulant use.

Munaza Riaz, Rakesh Bhattacharjee, Weihsuan Lo-Ciganic, Debbie Wilson, Emerson M Wickwire, Atul Malhotra, Christopher N Kaufmann, Haesuk Park

Erratum issuedAbstract read
In one paragraph

Article in Sleep, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Assessing mortality risk in narcolepsy: Evidence from population studies.PCN reports : psychiatry and clinical neurosciences · 2026
    Review
  2. Cardiovascular risk in narcolepsy: Comparison of type 1 and type 2 in a real-world cohort.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2026
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Munaza RiazDepartment of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Rakesh BhattacharjeeDepartment of Pediatrics, University of California San Diego School of Medicine, La Jolla, CA, USA.
Weihsuan Lo-CiganicDivision of General Internal Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0001-6590-4770
Debbie WilsonDepartment of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Emerson M WickwireSleep Disorders Center, Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Atul MalhotraDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, San Diego School of Medicine, University of California, La Jolla, CA, USA.
Christopher N KaufmannDepartment of Health Outcomes and Informatics, College of Medicine, University of Florida, Gainesville, FL, USA.
Haesuk ParkDepartment of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA.ORCID 0000-0003-3299-8111

Funding

Is Obstructive Sleep Apnea Important in the Development of Alzheimer's DiseaseR01AG063925 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALHOTRA, ATUL · 2020 to 2024
$3.7M
Underlying mechanisms of obesity-induced obstructive sleep apneaR01HL148436 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Atul Malhotra · 2020 to 2026
$3.4M
Sleep Apnea Endophenotypes: One Size Does Not Fit AllR01HL154926 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALHOTRA, ATUL · 2021 to 2025
$3.3M
The cardiovascular consequences of sleep apnea plus COPD (Overlap syndrome)R01HL166485 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Atul Malhotra · 2023 to 2026
$3.1M
VentNet: A Real-Time Multimodal Data Integration Model for Prediction of Respiratory Failure in Patients with COVID-19R01HL157985 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALHOTRA, ATUL, NEMATI, SHAMIM · 2022 to 2025
$2.9M
Developing a Diverse Next Generation of Leaders in Respiratory ScienceT32HL166127 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Laura Elise Crotty Alexander, Atul Malhotra · 2023 to 2026
$1.6M
NHLBI NIH HHS R01 HL148436NHLBI NIH HHS R01 HL154926NHLBI NIH HHS R01 HL157985NHLBI NIH HHS R01 HL166485NHLBI NIH HHS T32 HL166127NIA NIH HHS R01 AG063925Sleep Research Society Foundation 23-FRA-001
6 · The paper itself

Abstract

STUDY

objectivesWe aimed to assess associations between narcolepsy and cardiovascular disease risk while accounting for stimulant use in clinical practice.

methodsUsing 2005-2021 MarketScan Commercial and Medicare Supplemental databases, we identified patients with newly diagnosed narcolepsy using International Classification of Diseases, Ninth or Tenth, Clinical Modification diagnosis codes, were matched at a ratio of 1:3 patients without narcolepsy or hypersomnia using propensity score matching based on baseline demographics, comorbidities, and medication use. Primary outcomes included time to first (1) composite cardiovascular disease event and (2) major adverse cardiac event. Multivariable Cox proportional hazards regression models were used to compare outcome risks between groups, following PS matching, adjusting for time-fixed and time-varying variables, including stimulant use. Individual outcomes were examined separately and analyses were stratified by age, sex, and selected comorbidities.

resultsAfter PS matching, data from 134967 patients (mean [SD] age, 39.9 [16.8] years; 61.5% female) were included in final analyses. Following adjustment of baseline and time-varying covariates, patients with narcolepsy had increased risks of cardiovascular disease (adjusted hazard ratio, 1.89 [95% CI = 1.71 to 2.09]) and major adverse cardiac event (adjusted hazard ratio,1.95 [95% CI = 1.70 to 2.23]) compared with patients without narcolepsy. Results remained consistent across individual cardiovascular diseases and major adverse cardiac events. Subgroup analyses yielded similar findings.

conclusionsAfter adjusting for stimulant use, this cohort study found that patients with narcolepsy experienced increased risk of developing cardiovascular disease compared with patients without narcolepsy. This finding suggests that patients with narcolepsy may benefit from routine screening and monitoring for cardiovascular events. Statement of Significance This study enhances our understanding of the association between narcolepsy and cardiovascular events by employing a robust causal inference framework and adjusting for medications used to manage narcolepsy symptoms, which are known to be associated with cardiovascular risk. The large population-based cohort study included 34 562 patients with narcolepsy and 100 405 propensity score-matched patients without narcolepsy. Patients with narcolepsy had an increased risk of developing cardiovascular events compared to without narcolepsy controls, even after adjusting for medication use, including stimulants. These findings highlight the importance of routine cardiovascular screening and monitoring for patients with narcolepsy to mitigate potential risks.

Indexed as

Cardiovascular DiseasesCentral Nervous System StimulantsNarcolepsyAdultComorbidityFemaleHumansMaleMiddle AgedPropensity ScoreProportional Hazards ModelsRisk FactorsUnited StatesCentral Nervous System Stimulantscardiovascular diseasemajor adverse cardiac eventsnarcolepsyreal-world evidencestroke

Identifiers

PMID40657808
PMCPMC12710213

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.